Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 2, 2005, Pages 93-99

  Abletshauser, Claudia ^a   Brunel, Patrick ^b   Usadel, Klaus Henning ^c   Hanefeld, Markolf ^d  

^a Novartis Pharma GmbH Nuremberg   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c GOETHE UNIVERSITY   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Glimepiride; Nateglinide; Postprandial hyperglycaemia; Type 2 diabetes mellitus

Indexed keywords

GLIMEPIRIDE; GLUCOSE; INSULIN; LIPID; NATEGLINIDE; PLACEBO; POTASSIUM;

ADULT; AGED; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOOD INTAKE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPESTHESIA; HYPOGLYCEMIA; HYPOKALEMIA; INSULIN RELEASE; INSULIN RESPONSE; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TIME; TREATMENT OUTCOME;

EID: 19144367365     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050020701     Document Type: Article

References (31)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-86.
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
3. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997;20:1822-6.
4. Bastyr EJ III, Stuart CA, Brodows RG et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000;23:1236-41.
5. Monnier L, Lapinski H, Colette C. Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881-5.
6. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 1996; 39:1577-83.
7. The DECODE Study Group, The European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161:397-405.
8. Rodriguez BL, Lau N, Burchfiel CM et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality. The Honolulu heart program. Diabetes Care 1999; 22:1262-5.
9. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001;24:1397-402.
10. Hollander PA,. Schwartz SL, Gatlin MR et al. Importance of early insulin secretion: comparison of nateglinicle and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24:983-8.
11. Rosenstock J, Shen SG, Gatlin MR, Foley JE. Combination therapy with nateglinide and a thiazolidinedione improves glycaemic control in type 2 diabetes. Diabetes Care 2002;25:1529-33.
12. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycaemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660-5.
13. Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Diabetes Care 1996; 19:1194-9.
14. Niemi M, Neuvonen PJ, Kivisto KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001;70:439-45.
15. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomised study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998; 38:636-41.
16. Karara AH, Dunning BE, McLeod JF. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. J Clin Pharmacol 1999;39:172-9.
17. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22-9.
18. Bruttomesso D, Pianta A, Mari A et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999;48:99-105.
19. Hanefeld M, Haffner SM, Menschikowski M et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes Res Clin Pract 2002;55:221-7.
20. Monnier L, Colette C, Rabasa-Lhoret R et al. Morning hyperglycaemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. Diabetes Care 2002;25:737-41.
21. Podolsky D. Gasping for life. U.S. News and World Report [January 13], 61-65. 1997. Ref Type: Magazine Article.
22. Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42:222-9.
23. Gomis R, Novials A, Coves MJ, Casamitjana R, Malaisse WJ. Suppression by insulin treatment of glucose-induced inhibition of insulin release in non-insulin-dependent diabetics. Diabetes Res Clin Pract 1989;6:191-8.
24. Whitelaw DC, Clark PM, Smith JM, Nattrass M. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in type 2 diabetes mellitus. Diabet Med 2000;17:225-9.
25. Kahn SE, Montgomery B, Howell W et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001;86:5824-9.
26. Groop L, Luzi L, Melander A et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987; 36:1320-8.
27. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17:467-73.
28. Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996; 28:426-9.
29. Ligueros-Saylan M, Khalilieh S, Lee J et al. Nateglinide has a low hypoglycaemic potential in a missed-meal situation. Diabetologia 2000;43 (suppl. 1):A187.
30. Walter YH, Brookman L, Ma P, Grich JE, McLeod JF. Reduced risk of delayed hypoglycemia with nateglinide compared to repaglinide. Diabetes 2000;49(suppl 1):A128-A129.
31. Hanefeld M. Postprandial hyperglycaemia: noxious effects on the vessel wall. Int J Clin Pract Suppl 2002; 129:45-50.